Sativa Group PLC joined the NEX Exchange on 29th March 2018 as the first UK listed medicinal cannabis investment vehicle. Since then, the Company has changed its business strategy to capitalise on changes in the UK and European laws and regulations surrounding the cannabis industry. The Company has now established a UK board to follow a consumer investment strategy developing subsidiary businesses involved in the production, testing and compliance, research & development including pharmacology, commercialisation and sales & marketing of medicinal cannabis and cannabidiol products.
Sativa’s earlier business model was aimed to take advantage of well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector in North America. The Company invested in two Canadian companies; Rapid Dose Therapeutics, and Veritas Pharma Inc. These companies have enhanced Sativa’s market position by aiding valuable market research, particularly in the area of seed selection and dosing efficacy.
Following regulatory changes, Sativa has adapted its business strategy to incorporate the UK and European markets. The Company is capitalising on “Seed to Consumer” strategy, focusing on the smart-sourcing of the raw material, advanced extraction, manufacture, testing, distribution and research & development of medicinal cannabis and Cannabinoid products.
Two UK businesses, George Botanicals and PhytoVista Laboratories, are already fully operational, since being set up in June and July 2018, respectively. Other important future revenue streams, including the retail business Goodbody & Blunt, are at various points of development from early stage to commercial launch. The Company is excited to open the first of three pilot stores in Bath, after which Sativa intends roll-out a national franchise.